Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain | Zendy

Tero Tapiola | Zendy; Irina Alafuzoff | Zendy; SannaKaisa Herukka | Zendy; Laura Parkkinen | Zendy; Päivi Hartikainen | Zendy; Hilkka Soininen | Zendy; Tuula Pirttilä | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Author(s) -

Tero Tapiola,

Irina Alafuzoff,

SannaKaisa Herukka,

Laura Parkkinen,

Päivi Hartikainen,

Hilkka Soininen,

Tuula Pirttilä

Publication year - 2009

Publication title -

archives of neurology

Language(s) - English

Resource type - Journals

eISSN - 1538-3687

pISSN - 0003-9942

DOI - 10.1001/archneurol.2008.596

Subject(s) - cerebrospinal fluid , pathology , senile plaques , tau protein , medicine , alzheimer's disease , neurology , biomarker , dementia , amyloid (mycology) , neuropathology , tauopathy , immunohistochemistry , disease , neurodegeneration , chemistry , psychiatry , biochemistry

There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research